Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk

Figures

• 

  FIGURE 1. Cohort creation. Duplicate encounters were excluded and only the first admission was included in the case of duplicate patient entries. †Eligible doses included fluconazole ≥400 mg daily; apixaban 2.5, 5, or 10 mg twice daily; and rivaroxaban 15 mg once or twice daily or 20 mg once daily. DOAC, direct oral anticoagulant

• 

  FIGURE 2. Duration of DOAC therapy prior to evaluation. Dark gray bars represent patients receiving DOAC with fluconazole and light gray bars denote patients receiving a DOAC alone. DOAC, direct oral anticoagulant

• 

  FIGURE 3. Duration of concomitant fluconazole and DOAC therapy. Gray X represents the mean duration. Horizontal line within the box represents the median duration. Shaded box indicates the interquartile range. Whiskers denote the range, excluding outliers. Gray dots represent outliers. DOAC, direct oral anticoagulant

• 

  FIGURE 4. Patients with bleeding at 30 days. Dark gray bars represent patients receiving a DOAC with fluconazole. Light gray bars denote patients receiving a DOAC alone. *This difference was statistically significant. However, after adjusting for proven confounding variables (hemoglobin and concomitant carvedilol), the difference in bleeding was no longer statistically significant (AOR 1.71, 95% CI 0.85–3.40). 95% CI, 95% confidence interval; AOR, adjusted odds ratio; DOAC, direct oral anticoagulant

• 

  FIGURE 5. Type of bleeding. Dark gray bars represent patients receiving a DOAC with fluconazole. Light gray bars denote patients receiving a DOAC alone. DOAC, direct oral anticoagulant